Organization | Oncotherapeutics

Oncotherapeutics Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: West Hollywood CA United States (2002)

Organization Overview

First Clinical Trial

2004

NCT00085345

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

James R. Berenson, MD Inc. | Oncotherapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

armodafinil (nuvigil) (1 trial)

Drugs in Phase 2 Trials (16)

arsenic trioxide (trisenox) (1 trial)

bortezomib (velcade) (7 trials)

carfilzomib (kyprolis) (5 trials)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (5 trials)

elotuzumab (empliciti) (1 trial)

ixazomib (ninlaro) (1 trial)

lenalidomide (revlimid) (5 trials)

melphalan (alkeran) (4 trials)

methylprednisolone (medrol) (4 trials)

panobinostat (farydak) (1 trial)

pomalidomide (pomalyst) (3 trials)

prednisone (meticorten) (2 trials)

urea (7 trials)

vitamin c (3 trials)

Drugs in Phase 1 Trials (4)

pegylated arginine deiminase (1 trial)

ruxolitinib (jakafi) (1 trial)

selinexor (Xpovio) (1 trial)

sm153 lexidronam pentasodium (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 1)

Fatigue (Phase 3)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Plasmacytoma (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 19
# of Trial APIs: 21